ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1518

Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases

Matthew Thomas 1, Gavin Shaddick 2, Rachel Charlton 1, Charlotte Cavill 3, Richard Holland 4, Florenzo Iannone 5, Giovanni Lapadula 6, Simona Lapriore 5, Jakub Závada 7, Michal Uher 8, Karel Pavelka 9, Lenka Szczukova 10, Prodromos Sidiropolous 11, Irini Flouri 11, Burkhard Moeller 12, Michael J. Nissen 13, Ruediger B. Mueller 14, Almut Scherer 15, Neil McHugh1 and Alison Nightingale 1, 1University of Bath, Bath, United Kingdom, 2University of Exeter, Exeter, United Kingdom, 3Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, 4Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5University of Bari, Bari, Italy, 6Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, 7Institute of Rheumatology, Prague, Prague, Czech Republic, 8Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, 9Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 10Masaryk University, Brno, Czech Republic, 11University of Crete, Crete, Greece, 12University Hospital Bern, Bern, Switzerland, 13University Hospital Geneva, Geneva, Switzerland, 14Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, 15SCQM Foundation, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, combination therapies and comparative effectiveness and harms, DMARDs, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value of combination therapy in PsA remains unresolved. This study aimed to investigate whether TNFi combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more effective or improves TNFi drug survival compared to TNFi monotherapy.

Methods: Five PsA biologics cohorts were investigated between 2000 and 2015; the ATTRA registry (Czech Republic), the Swiss Clinical Quality Management PsA registry, the Hellenic Registry of Biologics Therapies (Greece), the University of Bari PsA biologics database (Italy) and the Bath PsA cohort (UK). Adults (≥18 years) with a clinical diagnosis of PsA who were new (first line) users of TNFi during the study period and registered in their respective database from TNFi initiation were eligible for inclusion. Exposure treatment groups at baseline included TNFi monotherapy, TNFi combination therapy with any csDMARD and a subgroup of TNFi combination therapy with MTX. Drug persistence was analysed using Kaplan-Meier and equality of survival using Log-Rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on: (a) the combined Italian and Swiss cohorts for change in rate of DAS-28; and (b) the combined Italian, Swiss and Bath cohorts for change in rate of HAQ.

Results: There were 2294 eligible patients identified from the contributing databases, of which 34% started TNFi in monotherapy and 66% in combination therapy. Patient characteristics and baseline disease activity and severity were generally similar across treatment groups within the databases. The majority of patients (82% monotherapy and 66% combination therapy) did not have changes to their baseline treatment regimen before discontinuing their first TNFi. In the Swiss (p=0.002), Greek (p=0.021) and Bath (p=0.014) databases, patients starting treatment on TNFi in combination with MTX had longer drug survival compared to monotherapy, whilst in Italy patients starting on monotherapy persisted longer (p=0.030) (Table 1). In all but the Czech database, men persisted significantly longer on their first TNFi than women (Table 1). In the combined Italian/Swiss dataset (n=1066) there was no significant difference in the rate of change of DAS28 between those on TNFi monotherapy versus TNFi combination with any csDMARD (combined Relative Risk (RRadj) 0.98 CI95 0.95-1.03) or when compared to those on TNFi+MTX (RRadj 0.98 CI95 0.95-1.02). Similarly, when also including the Bath cohort (n=1205), there was a comparable rate of change of HAQ in patients on TNFi monotherapy compared with combination with any csDMARD (RRadj 1.01 CI95 0.99-1.04) and when compared to those on TNFi+MTX combination (RRadj 1.02 CI95 0.99-1.05).

Conclusion: Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ. Combination therapy may, however, improve TNFi drug survival. Gender appears to be a major risk factor in determining TNFi survival, with males persisting on treatment for longer.


Table 1_Thomas et al.

Median survival times from TNFi initiation to discontinuation of first TNFi stratified by baseline treatment regimen and database.


Disclosure: M. Thomas, None; G. Shaddick, None; R. Charlton, None; C. Cavill, AbbVie, 2, Celgene Ltd, 2, Novartis, 2, 8; R. Holland, None; F. Iannone, None; G. Lapadula, None; S. Lapriore, None; J. Závada, None; M. Uher, None; K. Pavelka, AbbVie, 8, Abbvie, 5, 8, Amgen, 5, 8, BMS, 8, Egis, 5, 8, Lilly, 5, 8, MSD, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 8; L. Szczukova, None; P. Sidiropolous, None; I. Flouri, None; B. Moeller, AbbVie, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Merck, 2, 8, Novartis, 2, 8, Pfizer, 2, 8, UCB, 2, 9; M. Nissen, Abbvie, Celgene, Lilly, MSD, Novartis, Pfizer, 5, 8; R. Mueller, None; A. Scherer, None; N. McHugh, Pfizer, 2, Celgene, 2, Eli Lilly, 2, AbbVie, 5; A. Nightingale, None.

To cite this abstract in AMA style:

Thomas M, Shaddick G, Charlton R, Cavill C, Holland R, Iannone F, Lapadula G, Lapriore S, Závada J, Uher M, Pavelka K, Szczukova L, Sidiropolous P, Flouri I, Moeller B, Nissen M, Mueller R, Scherer A, McHugh N, Nightingale A. Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/tumour-necrosis-factor-inhibitor-monotherapy-versus-combination-therapy-with-conventional-synthetic-disease-modifying-anti-rheumatic-drugs-for-the-treatment-of-psoriatic-arthritis-a-combined-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tumour-necrosis-factor-inhibitor-monotherapy-versus-combination-therapy-with-conventional-synthetic-disease-modifying-anti-rheumatic-drugs-for-the-treatment-of-psoriatic-arthritis-a-combined-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology